The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells
Abstract
RATIONALE: Phosphodiesterase Type 5 (PDE5) inhibition represents a novel strategy for the treatment of pulmonary hypertension. OBJECTIVES: Our aim was to establish the distribution of PDE5 in the pulmonary vasculature and effects of PDE5 inhibition on pulmonary artery smooth muscle cells (PASMCs). METHODS AND MEASUREMENTS: PDE5 expression was examined by immunohistochemistry and Western blotting, in both normal and hypertensive lung tissues. DNA synthesis, proliferation, PDE activity, and apoptosis were measured in distal human PASMCs treated with soluble guanylyl cyclase activators (nitric oxide donors and BAY41-2272) and sildenafil. MAIN RESULTS: Cells containing PDE5 and alpha-smooth muscle actin occurred throughout the pulmonary vasculature, including obstructive intimal lesions. Three molecular forms of PDE5 were identified and protein expression was greater in hypertensive than control lung tissue. Most cyclic guanosine monophosphate hydrolysis (about 80%) in cultured cells was attributed to PDE5. Sildenafil induced a greater elevation of intracellular cyclic guanosine monophosphate levels compared with nitric oxide donors and BAY41-2272 (about 10-fold versus about 2-fold) and cotreatment had a synergistic effect, increasing cyclic nucleotide levels up to 50-fold. Dual stimulation of soluble guanylyl cyclase and inhibition of PDE5 activities also had significant downstream effects, increasing phosphorylation of vasodilator-stimulated phosphoprotein, reducing DNA synthesis and cell proliferation, and stimulating apoptosis, and these effects were mimicked by cyclic guanosine monophosphate analogs. CONCLUSIONS: Phosphodiesterase Type 5 is the main factor regulating cyclic guanosine monophosphate hydrolysis and downstream signaling in human PASMCs. The antiproliferative effects of this signaling pathway may be significant in the chronic treatment of pulmonary hypertension with PDE5 inhibitors such as sildenafil.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perkins, D. N., Pappin, D. J. C., Creasy, D. M., & Cottrell, J. S. (1999) · Electrophoresis · doi:10.1002/(sici)1522-2683(19991201)20:18<3551::aid-elps3551>3.0.co;2-2 · Cited by 8,203
Garg, U. C., & Hassid, A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114081 · Cited by 2,155
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections
Cattoretti, G., Pileri, S., Parravicini, C., Becker, M. H. G., Poggi, S., Bifulco, C., Key, G., D'Amato, L., Sabattini, E., Feudale, E., et al. (1993) · The Journal of Pathology · doi:10.1002/path.1711710205 · Cited by 721
Michelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Primary pulmonary hypertension
Runo, J. R., & Loyd, J. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13167-4 · Cited by 521
Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function
Rybalkin, S. D., Yan, C., Bornfeldt, K. E., & Beavo, J. A. (2003) · Circulation Research · doi:10.1161/01.res.0000087541.15600.2b · Cited by 511
Wallis, R. M., Corbin, J. D., Francis, S. H., & Ellis, P. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00042-9 · Cited by 504
Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., & Wilkins, M. R. (2001) · Circulation · doi:10.1161/hc2901.093117 · Cited by 488
Self-citationPharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man
WALKER, D. K. (1999) · Xenobiotica · doi:10.1080/004982599238687 · Cited by 401
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Simonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00004 · Cited by 616
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Senni, M., Paulus, W. J., Gavazzi, A., Fraser, A. G., Diez, J., Solomon, S. D., Smiseth, O. A., Guazzi, M., Lam, C. S. P., Maggioni, A. P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu204 · Cited by 355
Nitric oxide deficiency in pulmonary hypertension: pathobiology and implications for therapy
Tonelli, A. R., Haserodt, S., Aytekin, M., & Dweik, R. A. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.109911 · Cited by 86
Metadata
- Authors
- Wharton, J., Strange, J. W., Møller, G. M. O., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-01
- Volume
- 172
- Issue
- 1
- Pages
- 105-113
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2148797779
- Cited by
- 371
- References
- 41
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells. https://app.cochat.ai/papers/10.1164/rccm.200411-1587oc
- The paper
- Wharton, J., Strange, J. W., Møller, G. M. O., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R. (2005). Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200411-1587oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
